期刊文献+

92例多发性骨髓瘤患者合并肾功能衰竭的临床特点分析 被引量:2

Clinical characteristics of 92 multiple myeloma patients with renal failure
下载PDF
导出
摘要 目的分析多发性骨髓瘤(multiplemyeloma,MM)患者合并肾功能衰竭的临床及血清免疫固定特点。方法回顾性分析四川省人民医院1999~2012年5月收治的213例MM患者的临床及实验室检查资料。‘结果150例(70.4%)合并肾损害患者中67例(44.6%)以肾损害为首发症状收入肾内科。92例(43.2%)合并肾功能衰竭患者中63例作血清免疫固定电泳,IgG20例(31.7%),IgA22例(34.9%),IgD1例(1.6%),单纯轻链型18例(28.6%)。与肾功能正常组相比,合并肾功能衰竭患者贫血、高钙血症、高尿酸血症以及免疫分型为单纯轻链型的发生率显著升高(P〈0.05)。结论MM合并肾功能衰竭的发生率高,免疫分型为单纯轻链型发生率高,临床症状重,提示肾科医师收治的中老年肾功能衰竭患者应注意排除MM. Objective To investigate the clinical features of multiple myeloma(MM) patients with renal failure and understand the risk factors for MM with renal failure. Methods Clinical and laboratory data of 213 patients from January 1990 to May 2012 in Si- ehuan Provincial People's Hospital were retrospectively analyzed. Results There were 150 ( 150/213,70. 4% ) patients with renal im- pairment. Of the 150 cases, 67 cases (44. 6% )were firstly diagnosed in Nephrology Department, There were 92 (92/213,43.2%) pa- tients with renal failure. Of the 92 patients, immune electrophoresis was performed in 63 cases, in which 20 cases ( 31.7% ) were IgG type,22 cases(34. 9% )were IgA type,1 case( 1.6% )was IgD type and 18 cases(28.6% )were pure light chain type. The rates of se- vere anemia, hypercaleemia and hyperurieemia in patients with renal failure were more frequent than that in the patients with normal re- nal function ( P 〈 0. 05 ). Conclusion Renal failure was common in patients with multiple myeloma at the time of diagnosis, suggesting that nephrologists should pay attention to rule out multiple myeloma when treat the elderly patients with renal failure.
出处 《实用医院临床杂志》 2014年第1期78-80,共3页 Practical Journal of Clinical Medicine
关键词 肾功能衰竭 临床特点 多发性骨髓瘤 免疫分型 Renal impairment Clinical features Muhiple myeloma Immune typing
  • 相关文献

参考文献12

  • 1刘俊茹,李娟,陈媚,黄蓓晖,谷景立.硼替佐米+脂质体阿霉素+地塞米松方案治疗多发性骨髓瘤临床观察[J].实用医院临床杂志,2011,8(4):18-21. 被引量:8
  • 2Collins AJ,Kasiske B,Herzog C. Excerpts from the United States Renal Data System 2004 annual data report:atlas of end-stage renal disease in the United States[J].{H}American Journal of Kidney Disease,2005,(1 1):A5-7,S1-280. 被引量:1
  • 3Greipp PR,San Miguel J,Durie BG. International staging system for multiple myeloma[J].{H}Journal of Clinical Oncology,2005.3412-3420. 被引量:1
  • 4Dimopoulos MA,Kastritis E,Rosinol L. Pathogenesis and treatment of renal failure in multiple myeloma[J].{H}LEUKEMIA,2008.1485-1493. 被引量:1
  • 5Kyle RA,Gertz MA,Witzig TE. Review of 1027 Patients With Newly Diagnosed Multiple Myeloma[J].{H}Mayo Clinic Proceedings,2003.21-33. 被引量:1
  • 6Pozzi C,D'Amico M,Fogazzi GB. Light chain deposition disease with renal involvement:clinical characteristics and prognostic factors[J].{H}American Journal of Kidney Disease,2003.1154-1163. 被引量:1
  • 7Viertel A,Weidmann E,Ditting T. Management of renal complications in patients with advanced multiple myeloma[J].{H}Leukemia & lymphoma,2000,(5-6):513-519. 被引量:1
  • 8Bladé J,Fernández-Llama P,Bosch F. Renal failure in multiple myeloma:presenting features and predictors of outcome in 94 patients from a single institution[J].{H}Archives of Internal Medicine,1998,(17):1889-1893. 被引量:1
  • 9MacLennan ICM,Cooper EC,Chapman N. Renal failure in myelomatosis[J].{H}European Journal of haematology,1989,(51):60-65. 被引量:1
  • 10Deret S,Denoroy L,Lamarine M. Kappa light chain2associated Fanconi′s syndrome:molecular analysis of monoclonal immunoglobulin light chains from patients with and without intracellular crystals[J].{H}Protein Engineering,1999.363-369. 被引量:1

二级参考文献13

  • 1武永吉.多发性骨髓瘤[M]//张之南,沈悌.血液病诊断及疗效标准.3版.北京:科学出版社,2007:232-235. 被引量:14
  • 2Richardson P,Chanan-Khan A,Schlossman R,et al.Phase II trial of single agent bortezomib(VELCADE )in patients with previously untreated multiple myeloma(MM)[J].Blood,2004,104(11):336. 被引量:1
  • 3Harousseau JL,Attal M,Leleu X,et al.Bortezomib(VELCADE )plus dexamethasone as induction treatment prior to autologous stem cell transplantation(ASCT)in patients with newly diagnosed multiple myeloma:preliminary results of an IFM phase II study[J].Hematologica,2006,91(11):1498-1505. 被引量:1
  • 4Multiple myeloma,NCCN guidelins,version I,2010. 被引量:1
  • 5Bladé J,Samson D,Reece D,et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.Myeloma Subcommittee of the EBMT.European Group for Blood and Marrow Transplant[J].Br J Haematol,1998,102(5):1115-1123. 被引量:1
  • 6Oakervee HE,Popat R,Curry N,et al.PAD combination therapy(PS-341/bortezomib,doxorubicin and dexamethasone)for previously untreated patients with multiple myeloma[J].Br J Haematol,2005,129(6):755-762. 被引量:1
  • 7Palumbo A,Gay F,Bringhen S,et al.Bortezomib,doxorubicin and dexamethasone in advanced multiple myeloma[J].Annals of Oncology,2008,19(6):1160-1165. 被引量:1
  • 8Popat R,Oakervee HE,Hallam S,et al.Bortezomib,doxorubicin and dexamethasone(PAD)front-line treatment of multiple myeloma:updated results after long-term follow-up[J].Br J Haematol,2008,141(4):512-516. 被引量:1
  • 9Ma MH,Yang HH,Parker K,et al.The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents[J].Clinical Cancer Research,2003,9(3):1136-1144. 被引量:1
  • 10Orlowski RZ,Voorhees PM,Garcia RA,et al.Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies[J].Blood,2005,105(8):3058-3065. 被引量:1

共引文献7

同被引文献21

  • 1Stomp6r T, Zablocki M, Pankrac K, et al. Renal involvement in multiple myeloma. Pol Arch Med Wewn, 2012,122 ( 9 ) : 443 - 448. 被引量:1
  • 2Coekwell P, Hutehison CA. Management options for cast nephrop- athy in multiple myeloma. Curr Opin Nephrol Hypertens, 2010, 19(6) :550 -555. 被引量:1
  • 3Hutehison CA, Heyne N, Airia P, et al. Immunoglobulin free light t chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut - off haemodialysis. Nephrol Dial Transplant,2012,27 (10) -3823 - 3828. 被引量:1
  • 4Toly -Ndour C, Peltier J, Piedagnel R, et al. Acute renal failure with lambda light chain - derived crystals in a patient with IgD myeloma. Nephrol Dial Transplant ,2011,26 (9) :3057 - 3059. 被引量:1
  • 5Ying WZ, Allen CE, Curtis LM, et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest,2012,122 (5) : 1777 - 1785. 被引量:1
  • 6Leung N. Treating myeloma cast nephropathy without treating myeloma. J Clin Invest ,2012,122( 5 ) : 1605 - 1608. 被引量:1
  • 7Sethi S, Zand L, Leung N, et al. Membranoproliferative glomeru- lonephritis secondary to monoctonal gammopathy. Clin J Am Soc Nephro1,2010,5 (5) :770 - 782. 被引量:1
  • 8沈华英,石永兵,施晓松,宋锴,金东华,姜山.多发性骨髓瘤伴肾损害38例临床分析[J].苏州大学学报(医学版),2008,28(4):636-637. 被引量:5
  • 9刘宝利,高艳,陈以平.多发性骨髓瘤及其肾损害机制的认识[J].中国中西医结合肾病杂志,2009,10(2):170-171. 被引量:17
  • 10梁伟,熊祖应,罗琼,熊子波,郑磊,邵进.18例多发性骨髓瘤并肾损害的临床特点分析[J].中国中西医结合肾病杂志,2011,12(7):626-628. 被引量:10

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部